Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183


Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.

Zhu YJ, Zhang HB, Liu YH, Bai JP, Li Y, Liu LR, Qu YC, Qu X, Chen X.

Oncol Lett. 2017 Jul;14(1):655-664. doi: 10.3892/ol.2017.6249. Epub 2017 May 25.


The NF1 somatic mutational landscape in sporadic human cancers.

Philpott C, Tovell H, Frayling IM, Cooper DN, Upadhyaya M.

Hum Genomics. 2017 Jun 21;11(1):13. doi: 10.1186/s40246-017-0109-3. Review.


Genomic analysis of drug resistant small cell lung cancer cell lines by combining mRNA and miRNA expression profiling.

Chen Y, Yang X, Xu Y, Cao J, Chen L.

Oncol Lett. 2017 Jun;13(6):4077-4084. doi: 10.3892/ol.2017.5967. Epub 2017 Mar 31.


EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

Yan KS, Lin CY, Liao TW, Peng CM, Lee SC, Liu YJ, Chan WP, Chou RH.

Int J Mol Sci. 2017 May 31;18(6). pii: E1172. doi: 10.3390/ijms18061172. Review.


Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer.

Inamura K.

Cells. 2017 May 9;6(2). pii: E12. doi: 10.3390/cells6020012. Review.


Diagnostic and Therapeutic Potential of MicroRNAs in Lung Cancer.

Inamura K.

Cancers (Basel). 2017 May 9;9(5). pii: E49. doi: 10.3390/cancers9050049. Review.


Mutational analysis of multiple lung cancers: Discrimination between primary and metastatic lung cancers by genomic profile.

Goto T, Hirotsu Y, Mochizuki H, Nakagomi T, Shikata D, Yokoyama Y, Oyama T, Amemiya K, Okimoto K, Omata M.

Oncotarget. 2017 May 9;8(19):31133-31143. doi: 10.18632/oncotarget.16096.


SOX2 regulates multiple malignant processes of breast cancer development through the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis.

Liu K, Xie F, Gao A, Zhang R, Zhang L, Xiao Z, Hu Q, Huang W, Huang Q, Lin B, Zhu J, Wang H, Que J, Lan X.

Mol Cancer. 2017 Mar 14;16(1):62. doi: 10.1186/s12943-017-0632-9.


Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.

Allison Stewart C, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA.

Oncotarget. 2017 Apr 25;8(17):28575-28587. doi: 10.18632/oncotarget.15338.


Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.

Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, Sage J, Campbell JE, Ribich S, Rekhtman N, Dowlati A, Massion PP, Rudin CM, Poirier JT.

Cancer Cell. 2017 Feb 13;31(2):286-299. doi: 10.1016/j.ccell.2017.01.006.


Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.

Weinberg BA, Gowen K, Lee TK, Ou SI, Bristow R, Krill L, Almira-Suarez MI, Ali SM, Miller VA, Liu SV, Klempner SJ.

Oncologist. 2017 Feb;22(2):152-157. doi: 10.1634/theoncologist.2015-0511. Epub 2017 Feb 13.


Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status.

Suda K, Rozeboom L, Yu H, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR.

PLoS One. 2017 Feb 13;12(2):e0172209. doi: 10.1371/journal.pone.0172209. eCollection 2017.


High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.

Chang YL, Yang CY, Huang YL, Wu CT, Yang PC.

Oncotarget. 2017 Mar 14;8(11):18021-18030. doi: 10.18632/oncotarget.14935.


MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.

Mollaoglu G, Guthrie MR, Böhm S, Brägelmann J, Can I, Ballieu PM, Marx A, George J, Heinen C, Chalishazar MD, Cheng H, Ireland AS, Denning KE, Mukhopadhyay A, Vahrenkamp JM, Berrett KC, Mosbruger TL, Wang J, Kohan JL, Salama ME, Witt BL, Peifer M, Thomas RK, Gertz J, Johnson JE, Gazdar AF, Wechsler-Reya RJ, Sos ML, Oliver TG.

Cancer Cell. 2017 Feb 13;31(2):270-285. doi: 10.1016/j.ccell.2016.12.005. Epub 2017 Jan 12.


Translation from unconventional 5' start sites drives tumour initiation.

Sendoel A, Dunn JG, Rodriguez EH, Naik S, Gomez NC, Hurwitz B, Levorse J, Dill BD, Schramek D, Molina H, Weissman JS, Fuchs E.

Nature. 2017 Jan 26;541(7638):494-499. doi: 10.1038/nature21036. Epub 2017 Jan 11.


SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.

Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, Huang CH, de Stanchina E, Lowe SW, Ellis L, Beltran H, Rubin MA, Goodrich DW, Demichelis F, Sawyers CL.

Science. 2017 Jan 6;355(6320):84-88. doi: 10.1126/science.aah4307.


Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-βRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker.

Yokouchi H, Nishihara H, Harada T, Ishida T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Higuchi M, Honjo O, Minami Y, Watanabe N, Goto A, Suzuki H, Dosaka-Akita H, Isobe H, Nishimura M, Munakata M.

Oncotarget. 2017 Jun 13;8(24):39711-39726. doi: 10.18632/oncotarget.14410.


Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing.

Cho SY, Choi M, Ban HJ, Lee CH, Park S, Kim H, Kim YS, Lee YS, Lee JY.

Oncotarget. 2017 Jan 31;8(5):8095-8104. doi: 10.18632/oncotarget.14098.


Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting.

Eun K, Ham SW, Kim H.

BMB Rep. 2017 Mar;50(3):117-125. Review.


Cancer Cell Plasticity: Rapid Reversal of Chemosensitivity and Expression of Stemness Markers in Lung and Breast Cancer Tumorspheres.

Yakisich JS, Azad N, Kaushik V, Iyer AKV.

J Cell Physiol. 2017 Sep;232(9):2280-2286. doi: 10.1002/jcp.25725. Epub 2017 Mar 31.


Supplemental Content

Support Center